European Shortages Monitoring Platform training session on routine shortage reporting for marketing authorisation holders of CAPs, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 November 2024, 10:00 (CET) to 20 November

European Shortages Monitoring Platform training session on routine shortage reporting for marketing authorisation holders of CAPs, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 November 2024, 10:00 (CET) to 20 November 2024, 12:00 (CET)

Orphan designation: (S)-N-(1-(3-Fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide Treatment of soft-tissue sarcoma, 13/12/2023 Positive

Orphan designation: (S)-N-(1-(3-Fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide Treatment of soft-tissue sarcoma, 13/12/2023 Positive

Orphan designation: Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene Treatment of neuronal ceroid lipofuscinosis, 21/08/2019 Positive

Orphan designation: Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene Treatment of neuronal ceroid lipofuscinosis, 21/08/2019 Positive

Orphan designation: Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene Treatment of neuronal ceroid lipofuscinosis, 21/08/2019 Positive

Orphan designation: Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene Treatment of neuronal ceroid lipofuscinosis, 21/08/2019 Positive

Orphan designation: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Treatment of primary myelofibrosis, 25/08/2010 Positive

Orphan designation: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Treatment of primary myelofibrosis, 25/08/2010 Positive

Orphan designation: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Treatment of post-polycythaemia vera myelofibrosis, 25/08/2010 Positive

Orphan designation: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Treatment of post-polycythaemia vera myelofibrosis, 25/08/2010 Positive

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.